M. Dubuc will strengthen the Board’s capabilities in the fields of personalized medicine and companion diagnostics

Montpellier, France – Thursday, 26th of October, 2024 – SeqOne Genomics, a French company specialized in artificial intelligence-enhanced genomic analysis solutions, is pleased to announce the appointment of Martin Dubuc to its board of directors.

SeqOne Genomics is at the forefront of genomic data analysis in clinical applications, pioneering innovative software solutions that leverage artificial intelligence enabling more precise and personalized medicine.

Mr. Martin Dubuc, is a seasoned senior executive with Global experience who most recently headed up Biogen’s Global Digital Health division driving personalized and digital medicine. He brings over two decades of experience in the pharmaceutical industry at Pfizer, Merck&Co and Biogen across France, Europe and US combined with thought leadership expertise in digital health.

Sacha Loiseau, Ph.D., chairperson of SeqOne Genomics’ Board, stated: “I am thrilled to welcome Martin Dubuc to SeqOne’s Board. His deep insights into the pharmaceutical industry, combined with his knowledge of digital health technologies, will be
instrumental in taking SeqOne Genomics to the next level and providing the most advanced genomic analysis solutions for the pharmaceutical industry.”

“I was immediately seduced by the combination of people, hard science and technical
expertise underlying SeqOne’s genomic analysis platform, coupled with their focus on developing in-vitro diagnostics and companion diagnostics making personalized medicine a reality for patients and bringing innovative capabilities as a strategic
partner to LifeScience companies across the lifecycle.” commented Mr. Dubuc, “The exponential and converging progress of technologies underlying genomic testing opens a new era of opportunities. SeqOne is well positioned to make a meaningful
difference for patients partnering with LifeScience companies catalyzing precision medicine therapy development, genetic disease diagnosis, personalized medicine, and companion diagnostics”.

Dr. Nicolas Philippe, CEO and co-founder of SeqOne Genomics, concluded: “Martin Dubuc is a very strong addition to our Board of Directors. Martin’s shrewd business acumen and knowledge of the pharmaceutical industry have already proven to add significant value and will continue to help us as we strengthen our pharma offering and expand internationally.”

About SeqOne Genomics:
SeqOne Genomics offers high-performance genomic analysis solutions for healthcare
providers, treating patients suffering from cancer, rare and hereditary diseases as well
as pharmaceutical companies developing new therapies. The solution supports both
short read and long-read nanopore sequencing and leverages advanced machine
learning coupled with the company’s proprietary genomics platform to dramatically
reduce turnaround times and costs while delivering comprehensive and actionable
insights for personalized medicine. The company has won numerous awards including
the iLab award and the ARC cancer foundation’s Hélène Stark prize and has twice been
nominated for the prestigious Prix Galien award. Investors include Elaia, IRDI Capital
Investissement, Merieux Equity Partners, Omnes and Software Club.

Web: https://seqone.com

Contact:
Jean-Marc HOLDER
media@seqone.com
+33 (0) 9 54 40 42 84

• The Homologous Recombination Deficiency (HRD) biomarker identifies ovarian cancer patients likely to respond to PARP inhibitors.  
• SeqOne’s test simplifies the deployment of this test while reducing the number of inconclusive results, even when biopsies have low tumoral content.  
• Test accuracy was validated with the PAOLA-1 reference cohort and is presented at ESMO-GYNAE Barcelona on the 24th of February, 2023

Barcelona, Montpellier – February 22nd 2023:  SeqOne, the provider of new-generation genomic analysis solutions for personalized medicine, is announcing at the ESMO GYNAE conference a new HRD test that renders Homologous Recombination Deficiency (HRD) testing more accessible to Ovarian cancer patients. HRD status is key in the prescription of PARP inhibitor Olaparib, which improves survival of HRD-positive patients.

SeqOne’s approach simplifies the deployment of this test so that it can be performed by any well-equipped lab. To do this, SeqOne has based its test on a combination of two easily performed genomic analyses, a targeted gene panel and a low-pass whole genome, that together give excellent results when compared with reference tests.  The test has also been validated on multiple sequencers and reagents.  These results were clinically validated through a retrospective analysis of the PAOLA-1 cohort that was initially used to demonstrate the efficacy of Olaparib for HRD-positive patients. The cohort remains the gold standard for clinically validating all subsequent HRD tests. 

Another key focus was to ensure that actionable results could be obtained even with biopsies of low sample quality (low tumoral content),  as this has proved to be a major obstacle to delivering usable results in clinical routine environments.  SeqOne was able to deliver actionable HRD scores using samples of lower quality than most other tests; as little as 20% of cellularity and 50 nanograms of genetic material.  

“One of ARCAGY-GINECO ’s missions is to allow the validation of HRD testing through clinical evaluation on the PAOLA-1 cohort and to offer the medical professionals a reliable and objective assessment of test performance “. Said Pr. Pujade Lauraine, Medical Director of ARCAGY-GINECO. “SeqOne approached us early on in order to validate their test and have delivered a solution that is easy to implement and delivers great performance. I am glad that the clinical evaluation of their test is being presented today by my colleague Romain Boidot at ESMO GYNAE in Barcelona.”.

“Our objective was to deliver an easy-to-use test that would work even with samples of low tumoral content while affording medical professionals the assurance of test quality through a recognized certification process” said Nicolas Philippe, CEO of SeqOne.  “I am proud that we have delivered on this objective”.

“As a user of SeqOne’s solution,  we are pleased with the ease of use, accuracy and its tolerance to samples of low-tumoral content” said Marie-Pierre Wissler, a pathologist working at Cypath.  “It means we can return an HRD status more often than we could with previous vendors while at the same time reducing turnaround time.”

Clinical evaluation of SeqOne HRD is presented at ESMO GYNAE, in Barcelona on Feb 24th, 2023, by Romain Boidot, molecular biologist at the Centre Régional de Lutte contre le Cancer Georges François Leclerc (CGFL) Dijon

The SeqOne HRD score was validated using a retrospective analysis of 364 ovarian cancer patients from the PAOLA-1 phase 3 clinical trial. There is the same survival benefit for HRD+ patients when being treated with olaparib plus bevacizumab compared to bevacizumab alone, regardless of whether SeqOne HRD or Myriad myChoice® CDx test was used to form the HRD subgroup. In addition, SeqOne HRD has a smaller rate of inconclusive results compared to the inconclusive rate obtained with Myriad myChoice® CDx. Additional analyses to evaluate the HRD biomarker have been conducted: (i) a replication analysis on 48 individuals to test the reproducibility of the BRCA variant calling approach and (ii) a comparison of HRD testing using either NovaSeq and NextSeq sequencers to perform sWGS. Both analyses confirm the robustness of the SeqOne test.

– ENDS –

About SeqOne Genomics
SeqOne Genomics specializes in high-performance genomic analysis solutions for use in healthcare and life science –  hospitals, research institutions, and pharmaceutical companies -. SeqOne’s mission is to make genomic analysis more accessible and effective, in order to improve treatments for patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. 

SeqOne’s platform supports both short-read and long-read nanopore sequencing and leverages advanced machine learning coupled with the company’s proprietary genomics operating system to dramatically reduce turnaround times and costs while delivering comprehensive and actionable insights for personalized medicine.  https://www.seqone.com/

SeqOne media contacts
– Annie-Florence Loyer – afloyer@newcap.fr / +33 (6) 88 20 35 59
– Jean-Marc Holder – jm.holder@seqone.com / +33 (6) 03 24 57 56

About Cypath
CYPATH is an independent medical practice bringing together 75 private doctors specialized in Pathological Anatomy and Cytology, associated in SELAS (private practice company by simplified action) grouped on thirteen sites located in Auvergne-Rhône-Alpes, Bourgogne-Franche-Comté and Grand-Est. The group collaborates with nearly 90 healthcare institutions and many private practices, general or specialized (Dermatology, Radiology, Gynecology, Midwives …). https://www.cypath.fr/

About ARCAGY
ARCAGY (Association de Recherche sur les CAncers dont GYnécologiques) is a French nonprofit organization that conducts clinical research on gynecologic cancers. The organization’s mission is to stimulate research on gynecologic cancers, as well as to provide support and information to patients and their families.

ARCAGY-GINECO” is a group of clinicians and medical sites in France focused on clinical research to fight gynecological cancers, including ovarian, endometrial, and cervical cancers. It is dedicated to promoting research, innovation, and clinical trials in the field of gynecological oncology, and to improving the care and treatment of patients with these types of cancers. For more information: https://www.arcagy.org/